14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AKTX vs CAPR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Akari Therapeutics plc (AKTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKTX carries a Unified Composite Score of 43.0/100 (HOLD) at $6.70 (N/M Forward P/E, 0.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While AKTX currently prints a higher short-term Unified Composite Score (43.0/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-7.9% vs. +0.0% YoY).
Technical & Structure Timing Caution: AKTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.6); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKTX vs CAPR. Trailing 12-month operating profitability (AKTX 0.0% vs CAPR 0.0%) and valuation multiples (AKTX N/M vs CAPR 78.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AKTX vs CAPR Key Questions & Quantitative Answers
As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Akari Therapeutics plc (AKTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKTX carries a Unified Composite Score of 43.0/100 (HOLD) at $6.70 (N/M Forward P/E, 0.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AKTX currently prints a higher short-term Unified Composite Score (43.0/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-7.9% vs. +0.0% YoY). Technical & Structure Timing Caution: AKTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.6); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CAPR leads the Growth & Scale pillar: AKTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AKTX generates N/A in USD-normalized revenue versus $11M for CAPR. In operating R&D and SG&A reinvestment, AKTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.
CAPR screens cheaper on headline valuation multiples. AKTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKTX (-140.1% ROE) versus CAPR (-100.5% ROE) capital efficiency.
In options market volatility and institutional positioning, AKTX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (82.81β · 129% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.